Phosphate buffered saline (PBS)

BIOLOGICAL2 trials

Sponsors

PATH, Cytonics Corporation

Conditions

InfluenzaOsteoarthritisOsteoarthritis, KneeVaccine

Phase 1

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

CompletedNCT03300050

PATHInfluenza, Vaccine

Start: 2017-10-10End: 2019-08-09Updated: 2021-02-21

Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee

CompletedNCT06263270

Cytonics CorporationOsteoarthritis, Osteoarthritis, Knee

Start: 2024-06-01End: 2025-10-10Updated: 2025-12-26

Related Papers

A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.

2024-05-277 citations

Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity.

2022-12-1910 citations

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

2020-12-07271 citations

Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.

2019-12-0624 citations

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.

2019-10-17111 citations